andworldwide for its Captisol and cyclodextrin technologies and a comprehensiveFDA drug master file for client use

andworldwide for its Captisol and cyclodextrin technologies, and a comprehensiveFDA drug master file for client use. is a specialty pharmaceutical company developingproducts and licensing its Captisol technology. Captisol is currentlyincorporated in five FDA approved medications and marketed by three of thecompany`s licensees: Pfizer, Bristol-Myers Squibb and Prism Pharmaceuticals. He received a bachelor`s degree inmarketing from Southern Illinois University and a master`s degree in businessadministration from DePaul University About CyDex Pharmaceuticals, Inc.CyDex Pharmaceuticals, Inc. White previously held positions atMerck & Company and Stuart Pharmaceuticals.

In this role,White was responsible for marketing communications and product management forseveral therapeutic lines including cardiovascular, anti-infective/oncology,dermatology and immunology/transplantation. Our goal is todevelop a portfolio of Captisol-enabled® new medications for which we intend topursue FDA registration and commercialization directly.” Prior to joining CyDex, White held several positions at Astellas Pharma Inc.,including most recently vice president of portfolio/strategic planning and vicepresident of sales and marketing for the Critical Care division. “Rick`s extensive pharmaceutical career includes managing several product linesand successful launches,” said Odlaug. “His experience will be critical to CyDexas we seek strategic partners interested in combining their compounds and drugswith our Captisol technology to enable creation of new products.

As CyDex`s senior business development person, he alsowill be responsible for identifying new product opportunities in the acute carehospital market, as well as for expanding and managing the company`s strategicrelationships with pharmaceutical companies worldwide. At CyDex, White will be responsible for establishing partnerships and developingmarketing plans to accelerate commercialization of leading products in thecompany`s drug pipeline. White has been namedas the company`s vice president of business development and marketing He willreport to Theron E Odlaug, CyDex`s president and chief executive officer. Richard G.

White Appointed Vice President of Business Development and MarketingLENEXA, Kan.–(Business Wire)–CyDex Pharmaceuticals, Inc today announced that Richard G. Brightman, 281-367-1983Fax: 281-364-4346 Business Wire 2009. TETRA is an oil and gas services company, including an integrated calciumchloride and brominated products manufacturing operation that suppliesfeedstocks to energy markets, as well as other markets TETRA Technologies, Inc., The WoodlandsStuart M. The archivedwebcast will be available through the Company website for thirty days followingthe event.

The press release and its accompanying financialexhibits will be available on the Company website prior to the conference call.A replay of the call will be available at 877.660.6853 replay passcode accountno 286, conference ID 327377, for one week following the call. The call will also be available by liveaudio webcast and may be accessed through the Company website, tetratec , orthrough InvestorCalendar Stuart M Brightman, CEO, and Joseph M Abell,CFO, will host the call. (TETRA or the Company) (NYSE:TTI) will be releasingsecond quarter 2009 results on Thursday, August 6, 2009, and will be hosting aconference call at 10:30 a.m ET on that day to discuss the results The phonenumber for the call is 877.407.0778. THE WOODLANDS, Texas–(Business Wire)–TETRA Technologies, Inc. Theseforward-looking statements are made only as of the date hereof, and wedisclaim any obligation to update or revise the information contained inany such forward-looking statements, whether as a result of newinformation, future events or otherwise.For further information please contact:South Shore Resources Inc.(416) 281-3335Website at: 2009, Market Wire, All rights reserved.-0-. These forward-lookingstatements involve known and unknown risks, uncertainties and other factsthat could cause the actual future results of the Company to bematerially different from such forward-looking statements.